Ketamine's antidepressant effect: Literature review on clinical use;Effet antidépresseur de la kétamine: revue de la littérature sur l'utilisation de la kétamine dans la dépression

Encephale

Volumn 40, Issue 1, 2014, Pages 15-23

  De Maricourt, P ^a,b   Jay, T ^b   Goncalves P ^c   Loo H ^a   Gaillard, R ^a,b  

^a CENTRE HOSPITALIER SAINTE ANNE   (France)

^b INSERM   (France)

^c Clinique du Bois Bondy   (France)

Author keywords

Glutamate; Ketamine; Major depressive disorder; NMDA receptors; Treatment resistant depression

Indexed keywords

DÉPRESSION; DÉPRESSION RÉSISTANTE; GLUTAMATE; KETAMINE; KÉTAMINE; MAJOR DEPRESSIVE DISORDER; NMDA; NMDA RECEPTORS; TREATMENT-RESISTANT DEPRESSION;

COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; ELECTROCONVULSIVE THERAPY; HUMANS; INFUSIONS, INTRAVENOUS; KETAMINE; RECURRENCE; SUICIDE;

EID: 84894418292     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.encep.2013.09.001     Document Type: Article

References (80)

1. WHO The global burden of disease: 2004 update (Internet) [(cité 22 janv 2013). Disponible sur: http://www.who.int/healthinfo/global-burden- disease/2004-report-update/en/index.html] 2004
2. S.M. Stahl Stahl's essential psychopharmacology: neuroscientific basis and practical applications 2008 Cambridge University Press Cambridge
3. E. Vieta, and F. Colom Therapeutic options in treatment-resistant depression Ann Med 43 7 2011 512 530
4. D. Souery, G.I. Papakostas, and M.H. Trivedi Treatment-resistant depression J Clin Psychiatry 67 Suppl. 6 2006 16 22
5. M.E. Thase, and A.J. Rush When at first you don't succeed: sequential strategies for antidepressant nonresponders J Clin Psychiatry 58 Suppl. 13 1997 23 29
6. J. Schüttler, and H. Schwilden Modern Anesthetics 2008 Springer Berlin
7. S.A. Bergman Ketamine: review of its pharmacology and its use in pediatric anesthesia Anesth Prog 46 1 1999 10 20
8. R. Quibell, E.E. Prommer, and M. Mihalyo et al. Ketamine J Pain Symptom Manage 41 3 2011 640 649
9. J.H. Krystal, L.P. Karper, and J.P. Seibyl et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses Arch Gen Psychiatry 51 3 1994 199 214
10. J.W. Moore, D.C. Turner, and P.R. Corlett et al. Ketamine administration in healthy volunteers reproduces aberrant agency experiences associated with schizophrenia Cogn Neuropsychiatry 2011 1 18
11. P.R. Corlett, G.D. Honey, and J.H. Krystal et al. Glutamatergic model psychoses: prediction error, learning, and inference Neuropsychopharmacology 36 1 2011 294 315
12. A. Pilc, J.M. Wierońska, and P. Skolnick et al. Preclinical Psychopharmacology Biol Psychiatry 73 12 2013 1125 1132
13. S. Maeng, C.A. Zarate Jr., and J. Du et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3- hydroxy-5-methylisoxazole-4-propionic acid receptors Biol Psychiatry 63 4 2008 349 352
14. N. Li, R.-J. Liu, and J.M. Dwyer et al. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure Biol Psychiatry 69 8 2011 754 761
15. H.D. Schmidt, and R.S. Duman The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior Behav Pharmacol 18 5-6 2007 391 418
16. A. Becker, and G. Grecksch Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Test of predictive validity. Prog. Neuropsychopharmacol Biol Psychiatry 28 8 2004 1267 1277
17. F.C.C. Da Silva, M. Do Carmo de Oliveira Cito, and M.I. da Silva et al. Behavioral alterations and pro-oxidant effect of a single ketamine administration to mice Brain Res Bull 83 1-2 2010 9 15
18. Y. Tizabi, B.H. Bhatti, and K.F. Manaye et al. Antidepressant-like effects of low ketamine dose is associated with increased hippocampal AMPA/NMDA receptor density ratio in female Wistar-Kyoto rats Neuroscience 213 2012 72 80
19. M. Aan Het Rot, C.A. Zarate Jr., and D.S. Charney et al. Ketamine for depression: where do we go from here? Biol Psychiatry 72 7 2012 537 547
20. R.M. Berman, A. Cappiello, and A. Anand et al. Antidepressant effects of ketamine in depressed patients Biol Psychiatry 47 4 2000 351 354
21. C.A. Zarate Jr., J.B. Singh, and P.J. Carlson et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression Arch Gen Psychiatry 63 8 2006 856 864
22. J.C. Nelson The STAR*D study: a four-course meal that leaves us wanting more Am J Psychiatry 163 11 2006 1864 1866
23. J.W. Murrough, D.V. Iosifescu, and L.C. Chang et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial Am J Psychiatry 2013 [Epub ahead of print]
24. N. Diazgranados, L. Ibrahim, and N.E. Brutsche et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression Arch Gen Psychiatry 67 8 2010 793 802
25. C.A. Zarate Jr., N.E. Brutsche, and L. Ibrahim et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial Biol Psychiatry 71 11 2012 939 946
26. A.K. Ricke, R.J. Snook, and A. Anand Induction of prolonged mania during ketamine therapy for reflex sympathetic dystrophy Biol Psychiatry 70 4 2011 e13 e14
27. N. DiazGranados, L.A. Ibrahim, and N.E. Brutsche et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder J Clin Psychiatry 71 12 2010 1605 1611
28. C. Barbui, E. Esposito, and A. Cipriani Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies CMAJ 180 3 2009 291 297
29. M. Stone, T. Laughren, and M.L. Jones et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration BMJ 339 2009 b2880
30. R.B. Price, M.K. Nock, and D.S. Charney et al. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression Biol Psychiatry 66 5 2009 522 526
31. G.L. Larkin, and A.L. Beautrais A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department Int J Neuropsychopharmacol 14 8 2011 1127 1131
32. M. Aan het Rot, K.A. Collins, and J.W. Murrough et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression Biol Psychiatry 67 2 2010 139 145
33. J.W. Murrough, A.M. Perez, and S. Pillemer et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression Biol Psychiatry 2012 [Epub ahead of print]
34. M. Banasr, G.M.I. Chowdhury, and R. Terwilliger et al. Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole Mol Psychiatry 15 5 2010 501 511
35. S.L. Gourley, J.W. Espitia, and G. Sanacora et al. Antidepressant-like properties of oral riluzole and utility of incentive disengagement models of depression in mice Psychopharmacology 219 3 2012 805 814
36. G. Sanacora, S.F. Kendell, and Y. Levin et al. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms Biol Psychiatry 61 6 2007 822 825
37. C.A. Zarate Jr., J.L. Payne, and J. Quiroz et al. An open-label trial of riluzole in patients with treatment-resistant major depression Am J Psychiatry 161 1 2004 171 174
38. S.J. Mathew, J.W. Murrough, and M. Aan het Rot et al. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial Int J Neuropsychopharmacol 13 1 2010 71 82
39. L. Ibrahim, N. Diazgranados, and J. Franco-Chaves et al. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study Neuropsychopharmacology 37 6 2012 1526 1533
40. R. Ostroff, M. Gonzales, and G. Sanacora Antidepressant effect of ketamine during ECT Am J Psychiatry 162 7 2005 1385 1386
41. N. Okamoto, T. Nakai, and K. Sakamoto et al. Rapid antidepressant effect of ketamine anesthesia during electroconvulsive therapy of treatment-resistant depression: comparing ketamine and propofol anesthesia J ECT 26 3 2010 223 227
42. W.W. McDaniel, A.K. Sahota, and B.V. Vyas et al. Ketamine appears associated with better word recall than etomidate after a course of 6 electroconvulsive therapies J ECT 22 2 2006 103 106
43. L. Kranaster, J. Kammerer-Ciernioch, and C. Hoyer et al. Clinically favourable effects of ketamine as an anaesthetic for electroconvulsive therapy: a retrospective study Eur Arch Psychiatry Clin Neurosci 261 8 2011 575 582
44. X. Wang, Y. Chen, and X. Zhou et al. Effects of propofol and ketamine as combined anesthesia for electroconvulsive therapy in patients with depressive disorder J ECT 28 2 2012 128 132
45. C.G. Abdallah, M. Fasula, and B. Kelmendi et al. Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting J ECT 28 3 2012 157 161
46. I.K. Ho, and R.A. Harris Mechanism of action of barbiturates Annu Rev Pharmacol Toxicol 21 1981 11 83
47. Y. Kamiya, T. Andoh, and R. Furuya et al. Comparison of the effects of convulsant and depressant barbiturate stereoisomers on AMPA-type glutamate receptors Anesthesiology 90 6 1999 1704 1713
48. P. Blier, D. Zigman, and J. Blier On the safety and benefits of repeated intravenous injections of ketamine for depression Biol Psychiatry 72 4 2012 e11 e12
49. C.K. Loo, N. Katalinic, and J.B.B. Garfield et al. Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial J Affect Disord 142 1-3 2012 233 240
50. L.E. Phelps, N. Brutsche, and J.R. Moral et al. Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist Biol Psychiatry 65 2 2009 181 184
51. I.L. Petrakis, D. Limoncelli, and R. Gueorguieva et al. glutamate receptor antagonist response in individuals with a family vulnerability to alcoholism Am J Psychiatry 161 10 2004 1776 1782
52. D.A. Luckenbaugh, L. Ibrahim, and N. Brutsche et al. Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression Bipolar Disord 14 8 2012 880 887
53. G. Schumann, M. Johann, and J. Frank et al. Systematic analysis of glutamatergic neurotransmission genes in alcohol dependence and adolescent risky drinking behavior Arch Gen Psychiatry 65 7 2008 826 838
54. A.B. Petrenko, T. Yamakura, and N. Fujiwara et al. Reduced sensitivity to ketamine and pentobarbital in mice lacking the N-methyl-D-aspartate receptor GluRepsilon1 subunit Anesth Analg 99 4 2004 1136 1140
55. G. Salvadore, B.R. Cornwell, and V. Colon-Rosario et al. Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine Biol Psychiatry 65 4 2009 289 295
56. A.C. Nugent, N. Diazgranados, and P.J. Carlson et al. Neural correlates of rapid antidepressant response to ketamine in bipolar disorder Bipolar Disord 2013 [Epub ahead of print]
57. H.S. Mayberg, S.K. Brannan, and R.K. Mahurin et al. Cingulate function in depression: a potential predictor of treatment response Neuroreport 8 4 1997 1057 1060
58. R.J. Davidson, W. Irwin, and M.J. Anderle et al. The neural substrates of affective processing in depressed patients treated with venlafaxine Am J Psychiatry 160 1 2003 64 75
59. R.M. Benca, W.H. Obermeyer, and R.A. Thisted et al. Sleep and psychiatric disorders. A meta-analysis Arch Gen Psychiatry 49 8 1992 651 668 [discussion 669-670]
60. W.C. Duncan Jr., K.D. Pettigrew, and J.C. Gillin REM architecture changes in bipolar and unipolar depression Am J Psychiatry 136 11 1979 1424 1430
61. W.C. Duncan, S. Sarasso, and F. Ferrarelli et al. and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder Int J Neuropsychopharmacol 16 2 2013 301 311
62. W.C. Duncan Jr., J. Selter, and N. Brutsche et al. Baseline delta sleep ratio predicts acute ketamine mood response in major depressive disorder J Affect Disord 145 1 2013 115 119
63. C.A. Zarate Jr., D.C. Mathews, and M.L. Furey Human Biomarkers of Rapid Antidepressant Effects Biol Psychiatry 73 12 2013 1142 1155
64. G. Salvadore, J.W. Van der Veen, and Y. Zhang et al. An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression Int J Neuropsychopharmacol 15 8 2012 1063 1070
65. E. Haroon, C.L. Raison, and A.H. Miller Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior Neuropsychopharmacology 37 1 2012 137 162
66. G. Hasler, J.W. Van der Veen, and T. Tumonis et al. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy Arch Gen Psychiatry 64 2 2007 193 200
67. W.C. Drevets, J.L. Price, and M.L. Furey Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression Brain Struct Funct 213 1-2 2008 93 118
68. M. Walter, A. Henning, and S. Grimm et al. The relationship between aberrant neuronal activation in the pregenual anterior cingulate, altered glutamatergic metabolism, and anhedonia in major depression Arch Gen Psychiatry 66 5 2009 478 486
69. E.K. Silberman, V.I. Reus, and D.C. Jimerson et al. Heterogeneity of amphetamine response in depressed patients Am J Psychiatry 138 10 1981 1302 1307
70. C.J.A. Morgan, L. Muetzelfeldt, and H.V. Curran Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study Addiction 105 1 2010 121 133
71. H.V. Curran, and L. Monaghan In and out of the K-hole: a comparison of the acute and residual effects of ketamine in frequent and infrequent ketamine users Addiction 96 5 2001 749 760
72. R. Narendran, W.G. Frankle, and R. Keefe et al. Altered prefrontal dopaminergic function in chronic recreational ketamine users Am J Psychiatry 162 12 2005 2352 2359
73. Y. Liao, J. Tang, and P.R. Corlett et al. Reduced dorsal prefrontal gray matter after chronic ketamine use Biol Psychiatry 69 1 2011 42 48
74. C.A. Zarate Jr., D. Mathews, and L. Ibrahim et al. A randomized trial of a low-trapping nonselective n-methyl-d-aspartate channel blocker in major depression Biol Psychiatry 2012 [pii: S0006-3223(12)00941-9]
75. G. Sanacora, M.A. Smith, and S. Pathak et al. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects Mol Psychiatry 2013 [Epub ahead of print]
76. J. Burgdorf, X.-L. Zhang, and K.L. Nicholson et al. GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects Neuropsychopharmacology 38 7 2013 1374
77. D.B. Carr, L.C. Goudas, and W.T. Denman et al. Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study Pain 108 1-2 2004 17 27
78. M.I. Blonk, B.G. Koder, and P.M.L.A. Van den Bemt et al. Use of oral ketamine in chronic pain management: a review Eur J Pain 14 5 2010 466 472
79. C.A. Zarate Jr., N. Brutsche, and G. Laje et al. Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression Biol Psychiatry 72 4 2012 331 338
80. E. Dolgin Rapid antidepressant effects of ketamine ignite drug discovery Nat Med 19 1 2013 8